Various strategies for analysing SNP markers and genotyping have been published with the goal of obtaining informative profiles from biological samples that contain only small amounts of template and/or degraded DNA. In this study, a multiplex assay of 52 autosomal single-nucleotide polymorphisms (SNPs) was used to analyse 438 individuals from urban populations from different regions of Colombia, as well as a sample of 50 Native American individuals of the Pastos ethnic group from Nariño. To determine if significant differences in these 52 SNPs exist between the distinct regions of Colombia, genetic distance and admixture analyses were performed based on the available data for 17 different Colombian population groups and for population groups from Africa, Europe and America. The results demonstrate significant differences between the populations from the Southwest Andean, Central-West Andean, Central-East Andean, Orinoquian and northern Colombian Pacific Coast regions. Most of the regions exhibited a European and Native American admixture. One exception is the population from the region of Chocó (on the northern Pacific Coast), which exhibits a high proportion of African admixture (54 %). From the observed genetic backgrounds, it is possible to conclude that a single reference database for the entire country would not be suitable for forensic purposes. The allele frequencies and the forensically relevant parameters were calculated for all of the markers in each Colombian region with significant values for the combined matching probability (power of discrimination ≥0.99999999999999990) and the combined probability of exclusion (≥0.9990) in trios that were obtained from all of the population groups.

No abstract

No abstract

Background:Cutaneous manifestations are observed in 59–85% of patients with SLE but less than 5% developed BSLE. In the GLADEL cohort, the prevalence is 0.41%. BSLE literature in children is scarceObjectives:to describe the clinical characteristics of the patients with BSLEMethods:series of cases between 2010-2019 of two reference centers. The cases met Camisa and Grimwood criteria for BSLEResults:5 cases had bullous lesions that resolved with residual hypopigmentation. One case had focal seizure and other patient had arthritis with leukopenia and thrombocytopenia. 2 patients had proteinuria <500 mg/24 hours. There were no cases of lupus nephritis. The median SLEDAI-2K score was 12 (IR: 8-17). All had ANAs in titers greater than 1:160 and four had anti-DNA (+). 5 patients had anti-RNP and 4 had anti-Sm. One case had anti-Ro/anti-La. All presented low C3 and 80% had low C4. 80% had ESR ≥20 mm/hour and CRP greater than 0.5 mg/dl in 60%. All presented clinical response with glucocorticoids and dapsone; one patient had methemoglobinemia that improved. At 3 months, the blisters did not recur in 4 patients except one case that presented relapse due to inadherence.Histologically, the most common finding was subepidermal blisters with neutrophils in the papilar dermis. DIF showed linear deposits of Igs and complement in 4 cases and granular deposits in one case; IgG/IgM were in 5 of the samples. IgA was positive in 60% and C3 in 80%Conclusion:In this series, BSLE was associated with neuropsychiatric, joint and haematological involvement in 40% of patients, without lupus nephritis. Such abnormalities had a parallel course to skin involvement, without recurrences. BSLE tends to have a single-phase behavior and in children unlike adults, severe renal involvement is uncommonReferences:[1]Pons-Estel GJ, et al. Lupus 2018; 27(10): 1753-1754Disclosure of Interests:None declared

BackgroundThe medical meetings are a tool to help us be able to escalate and actualize the medical knowledge and their quality is a responsibility of Colleges and Institutions.ObjectivesTo assess the academic level of four types of different annual Meeting of RheumatologyMethodsWe used as support information the summaries published in the supplements of the journal Reumatologia Clinica, SE1 Vol. 12 of February 2016, the supplement SE 1 Vol. 13 of February 2017, the application for electronic media of the ACR/ARHP 2016 of the American Congress of Rheumatology 2016 and the website for abstracts of ,EULAR 2017 dedicated to the surveys presented in the XLIV Mexican Congress of Rheumatology, XLV Mexican Congress of Rheumatology and the 2016 ACR/ARHP Annual Meeting, and EULAR 2017 respectively, of each survey we was obtained information about of the diverse pathologies, the type of trial, content and population referred (adults versus children).Results275, 340, 3275 and 4129 were presented in the XLIV Mexican Congress of Rheumatology, XLV Mexican Congress of Rheumatology, the 2016 ACR/ARHP Annual Meeting and EULAR 2017 respectively. Rheumatoid arthritis (RA) was the most common pathology with 23%, 26%, 21% and 27% in CMR 44, CMR 45, ACR 2016 and EULAR 2017 respectively, followed by systemic lupus erythematosus, third place was vasculitis, beside in international congress was the spondyloartrhitis. Highlighted, RA the items about of clinic manifestations were accounted for almost 30% in the Mexican congress and almost 20% in ACR and EULAR.Observational studies accounted for almost 40% in Mexican congresses vs. 33% in ACR 2016 and 55% in ,EULAR 2017 beside surveys about of basic research were minimal in Mexican congress, but in ACR 2016 accounted for 21% and 12% in .EULAR 2016 The trials about of Paediatric Rheumatology were 12.3%, 5.5% and 4.9% in CMR 44, CMR 45 and ACR 2016 respectively.Abstract AB1381 – Figure 1percentage of rheumatic diseaseConclusionsRheumatology Meeting constitutes a support to obtain the adequate medical knowledge based in evidence, in this important branch of Medicine. We require of the collaborative efforts to achieve best goals with controlled studies, clinical and basic assays, increasing the Meeting’s quality.References[1] Serrano KJ, Yu M, Riley WT, Patel V, Hughes P, Marchesini K, Atienza AA. Willingness to Exchange Health Information via Mobile Devices: Findings From a Population-Based Survey. Ann Fam Med. 2016Jan-Feb;14(1):34–40. doi: 10.1370/afm.1888.[2] Studdert DM, Mello MM, Gawande AA; Ghandi TK, Kachalia A, Yoon C, et al. Claims, Errors, and Compensation Payments in Medical Malpractice Litigation. N Engl J Med2006;354:2024–33.[3] Bothwell LE, Greene JA, Podolsky SH, and Jones DS. Assessing the Gold Standard—Lessons from the History of RCTs. N Engl J Med2016; 374:2175–81.[4] Fiore LD and Lavori PW. Integrating Randomized Comparative Effectiveness Research with Patient Care. N Engl J Med2016; 374:2152–8.Disclosure of InterestNone declared